Basel, June 2, 2014 - Novartis today announced data showing Zykadia(TM) (ceritinib, previously known as LDK378) shrank tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), including those who had received previous treatment with an ALK inhibitor as well as patients receiving one for the first time. Results were also observed in patients with ALK+ NSCLC who entered the study with brain metastases[1].
The study is being presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Novartis study shows Zykadia(TM) shrank tumors in the majority of patients with ALK+ NSCLC, regardless of prior ALK treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.